drugset / Trial / NCT02583009

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea

NCT02583009

Phase 2 Completed 216 enrolled Amorepacific Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This clinical study is to determine the optimum dose of PAC-14028 cream in a therapeutic confirmatory clinical study by evaluating the safety and therapeutic equivalence of PAC-14028 cream 0.1%, 0.3% and 1.0% in patients with rosacea.

Timeline

Start
2014-10
Primary completion
2016-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject PAC-14028 Unknown 0.1 % Topical
Subject PAC-14028 Unknown 0.3 % Topical
Subject PAC-14028 Unknown 1 % Topical

Indications